According to Renub Research Latest Report United States in-vitro diagnostics (IVD) market is forecasted to grow from US$ 42.71 billion in 2024 to US$ 65.01 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4.78% between 2024 and 2030. The expansion of this market is fueled by advances in diagnostic technologies, increased demand for early disease detection, and the rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer.
Overview of the US In-Vitro Diagnostics Market
In-vitro diagnostics (IVD) refers to medical tests performed on human samples—such as blood, urine, or tissue—outside the body to diagnose diseases, monitor health conditions, and guide treatment decisions. IVD encompasses a wide range of products, including test kits, laboratory reagents, and diagnostic instruments, used to detect infections, cancer, genetic disorders, and cardiovascular diseases.
In the United States, IVD plays a critical role in improving patient outcomes, enabling early detection, personalized treatment, and chronic disease management. The healthcare system increasingly relies on IVD for routine checkups, treatment planning, and monitoring disease progression. The integration of IVD technologies with molecular diagnostics, point-of-care testing, and automation has contributed to more efficient healthcare delivery and better patient care nationwide.
👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report
Key Growth Drivers of the US IVD Market
Technological Advancements in Diagnostics
One of the primary growth drivers for the US IVD market is rapid innovation in diagnostic technology. Advances in molecular diagnostics, next-generation sequencing, and automated testing platforms have made diagnostics faster, more accurate, and minimally invasive. Early detection of cancer, genetic disorders, and infectious diseases has become more reliable due to these technological breakthroughs.
Point-of-care testing (POCT) and home-based diagnostic kits have also enhanced patient accessibility, allowing individuals to monitor their health conveniently outside traditional healthcare settings. For example, in July 2023, Siemens Healthineers launched a next-generation analyzer designed for clinical chemistry and immunoassay testing. This instrument is compatible with standalone labs as well as satellite laboratories, improving both the speed and precision of diagnostic testing.
Rising Incidence of Chronic Diseases
The increasing prevalence of chronic conditions is a major driver of the US IVD market. Conditions such as diabetes, cardiovascular diseases, and cancer require regular diagnostic testing for management and treatment. According to America’s Health Rankings, over 54 million seniors aged 65 and above live in the US, representing 16.5% of the population, and this number is projected to surpass 85 million by 2050.
Early detection and monitoring of chronic diseases are critical for effective intervention. For instance, the American Cancer Society estimated 1.96 million new cancer cases in 2023, along with 609,820 deaths, highlighting the demand for timely and precise diagnostics. This trend underscores the growing importance of IVD technologies in improving patient outcomes and managing chronic health conditions.
Government Initiatives and Healthcare Reforms
Government support through healthcare reforms and increased funding is also promoting IVD market growth. Programs such as the Affordable Care Act (ACA) have expanded preventive healthcare services, including routine diagnostic testing. Public health initiatives focusing on early detection and personalized medicine have further contributed to the adoption of advanced IVD technologies.
Investment in research and development by federal and state agencies encourages innovation in diagnostic methods, enabling the development of more accurate, reliable, and efficient IVD solutions. These initiatives collectively support the growth trajectory of the US IVD market.
Market Challenges
Regulatory Hurdles
The regulatory environment in the US poses a challenge for IVD manufacturers. The FDA regulates IVD products to ensure safety and efficacy, which involves lengthy approval processes, extensive testing requirements, and adherence to international standards.
Meeting these regulatory standards can delay product launches and increase operational costs. Manufacturers must also comply with quality control, labeling, and post-market surveillance requirements, which can be resource-intensive and challenging for both new entrants and established companies.
High Cost of IVD Products
The high cost of advanced IVD technologies is another barrier to market expansion. Cutting-edge instruments, reagents, and consumables are expensive, limiting their accessibility, particularly in rural or underserved areas. Healthcare providers may face financial constraints in implementing these advanced diagnostics as part of routine care, which can restrict widespread adoption.
Emerging Technologies in the US IVD Market
PCR Technology
Polymerase Chain Reaction (PCR) continues to experience strong growth in the IVD market due to its versatility, sensitivity, and broad applications. PCR-based tests play a key role in diagnosing infectious diseases, genetic disorders, and cancers, providing rapid and precise results.
Advances in real-time PCR (qPCR) and digital PCR are further enhancing the accuracy and efficiency of diagnostic testing. These technologies are increasingly adopted in laboratories and healthcare facilities, contributing to overall market growth.
IVD Instruments
Diagnostic instruments represent the largest product segment in the US IVD market. These instruments are essential for efficient and accurate diagnostic testing, enabling high throughput, optimized workflow, and improved reliability. The focus on advanced automated systems addresses the increasing demand for high-performance diagnostic solutions in hospitals and laboratories.
Hematology Testing
The hematology segment is projected to be one of the fastest-growing areas in the US IVD market. Blood disorders such as anemia, leukemia, and hemophilia are becoming more prevalent, driving demand for accurate and timely testing. Technological advancements in hematology analyzers—including enhanced automation and integrated parameters—further stimulate growth in this segment, making it a key contributor to the overall market expansion.
👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report
US IVD Market Segmentation
Test Types:
ELISA & CLIA
PCR
Rapid Test
Fluorescence Immunoassays (FIA)
In Situ Hybridization
Transcription Mediated Amplification
Sequencing
Colorimetric Immunoassay
Radioimmunoassay (RIA)
Isothermal Nucleic Acid Amplification Technology
Others
Product Types:
Reagents
Instruments
Services
Applications:
Immunochemistry
Clinical Chemistry
Hematology
Coagulation
Molecular Diagnostics
Microbiology
Others
Major Players in the US IVD Market
Key companies driving innovation in the US IVD industry include:
Roche Diagnostics
Danaher Corporation
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
BioMérieux
Abbott Laboratories
Sysmex Corporation
Recent Developments
In March 2023, Atila Biosystems and Stilla Technologies collaborated to co-sell digital PCR equipment, combining kits and assays with Stilla’s Naica PCR instruments.
In January 2023, QIAGEN launched the EZ2 Connect MDx platform, enhancing automation in sample processing compatible with PCR, qPCR, and other downstream applications.
These strategic launches highlight the focus on automation, precision, and efficiency in the US IVD market, catering to increasing demand for rapid and reliable diagnostics.
Future Outlook
The US IVD market is expected to continue its growth trajectory, driven by technological innovation, the rising burden of chronic diseases, government support, and increasing awareness of early disease detection. While challenges such as regulatory compliance, high costs, and infrastructure limitations remain, ongoing advancements in PCR, hematology, and automated diagnostic instruments will expand accessibility, efficiency, and precision in healthcare delivery.
The integration of personalized medicine and point-of-care diagnostics is anticipated to reshape the US healthcare landscape, making in-vitro diagnostics an essential component of modern medical practice. As healthcare providers adopt advanced IVD solutions, patients are likely to benefit from earlier disease detection, tailored treatment plans, and improved overall health outcomes, further reinforcing the market’s significance in the United States.
Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.
link